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Abstract
Background: Complex peripheral nerve injuries of the hand include at least 300,000 cases per year in Europe. The
standard treatment involves a microsurgical end-to-end suture of traumatic sensory nerve lesions of the hand without a
gap. The objective of this study protocol is to evaluate whether the additional use of a chitosan nerve tube in primary
repair of traumatic sensory nerve lesions of the hand without a gap has an effect on the recovery of sensitivity.
Methods/Design: We planned a randomized double-blind controlled multicenter trial with a parallel group design in
order to show superiority for the additional use of a chitosan nerve tube. This study will enroll 100 participants with
traumatic sensory nerve lesions of the hand without a gap from three Trauma Care Centers. Participants will be
randomized in a 1:1 ratio to primary microsurgical repair of the injured nerve with the additional use of a chitosan nerve
tube or direct tension free microsurgical repair of the injured nerve alone. The static two-point discrimination of the
injured finger after 6 months will be the primary outcome parameter.
Discussion: In the proposed study, the additional use of a chitosan nerve tube for a primary microsurgical repair of
traumatic sensory nerve lesions of the hand without a gap will be evaluated in a prospective randomized double-blind
controlled multicenter trial for the first time to create the highest possible evidence for the procedure.
Trial registration: ClinicalTrials.gov Identifier: NCT02372669.
Protocol Registration Receipt on 27 February 2015.
Keywords: Nerve lesions of the hand, peripheral nerve surgery, nerve tube, sensory outcome
Background
Complex peripheral nerve injuries of the hand include at
least 300,000 cases per year in Europe [1]. In recent de-
cades, considerable efforts have been made to support
peripheral nerve regeneration but often with limited and
minor success. At least one-third of patients will never
regain normal sensitivity of the injured finger [2]. Subse-
quently, nerve dysfunction may lead to impaired func-
tion of the whole hand. This is especially true if the
thumb as well as the index and small fingers are
affected. Painful neuroma formation is frequently ob-
served after peripheral nerve injuries of the hand. Sixty
percent of these patients are observed with persistent
pain lasting for years in up to 10 % [3–5].
Injured nerves do not spontaneously restore their
function. Continuity of the nerve has to be re-
established by microsurgical intervention. Standard
treatment for traumatic sensory nerve lesions of the
hand without a gap is an end-to-end suture, whereas
nerve gaps are generally treated using autologous nerve
grafts [6]. However, functional results often are disap-
pointing, and painful neuroma formation is frequently
observed after nerve repair. Moreover, autologous nerve
grafting comes along with significant donor site morbid-
ity [7]. To overcome this problem, alternative treatment
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options such as biosynthetic nerve grafts (little bio-
absorbable implantable tubes) have been developed, pri-
marily for the repair of short gap injuries. Nerve tubes
should bridge the gap in this situation, protect the nerve
from scar formation, and guide the regenerating axons
to the distal stump [7]. The basic design of these nerve
tubes is similar, but they are made of different absorb-
able biomaterials. For chitosan, a bioactive effect is re-
ported [8–11].
This study should focus on the use of nerve tubes in
addition to the primary microsurgical repair of traumatic
sensory nerve lesions of the hand without a gap. So far,
evidence for this approach is lacking. However, consoli-
dated findings regarding tension in nerve repair and re-
construction of nerve gaps using chitosan tubes, as well
as the biomaterial chitosan itself, are available to support
the procedure.
Above all, tension in the repaired nerve prohibits the
healing process [12]. The use of a nerve tube allows a
tension-free suture. Possibly, that is the reason why
nerve repair using a nerve tube bridging a gap of several
millimeters was shown to have even better results than
primary repair in injuries without nerve loss [13].
Promising clinical results have already been observed
for nerve gap reconstruction using nerve tubes. The
meta-analysis of Meek et al. summarizes the available lit-
erature and reports good and excellent results after
11 months in 75 % of the cases [14]. However, the au-
thors still conclude that prospective randomized con-
trolled trials with a systematic comparison of standard
treatment and biosynthetic implants are lacking and that
a systematic evaluation of only one biomaterial is re-
quired. Whether the repair of nerve lesions without a
gap using a chitosan nerve tube can obtain comparable
results is uncertain.
Chitosan, a derivative of chitin, is a biocompatible and
biodegradable material and is similar to natural glycos-
aminoglycans. In vivo studies showed positive effects on
the survival and orientation of the Schwann cells [8], as
well as on the survival and differentiation of the neur-
onal cells [9, 10]. Furthermore, the substance itself
seems to prevent painful neuroma [11]. Therefore, it po-
tentially is the ideal material for nerve tube reconstruc-
tion. In this study, chitosan nerve tubes will be tested for
use in treating traumatic sensory nerve lesions of the
hand without a gap for the first time.
The assessment of sensory recovery after peripheral
nerve surgery also remains challenging. Sensitivity of the
hand is a complex process and can only be assessed with
several tests addressing a variety of partial functions.
Strictly speaking, the two-point discrimination (2-PD) is
just an assessment tool for tactile gnosis. Tactile gnosis is
the ability to recognize shapes and is a marker of func-
tional recovery [15]. An age-related decline was shown in
healthy individuals [16]. Based on that fact, nerve regener-
ation has often been postulated also to decrease with age
[17], but this has not yet been proven. More importantly,
interfering variables such as the distance from the lesion
to the finger pulp exist. This distance was the only inter-
fering variable that was shown in Meeks meta-analysis
[14]. However, measuring the two-point discrimination
provides a ratio of scaled values, making it particularly
suitable for a scientific approach. The Semmes-Weinstein
monofilament test, in contrast, assesses the ability for the
perception of cutaneous pressure and is a marker for re-
innervation in a stricter sense but does result in categories
and thereby in a minor level of measurement [18].
The objective of this study protocol is to evaluate
whether the additional use of a chitosan nerve tube in
the primary microsurgical repair of traumatic sensory
nerve lesions of the hand without a gap has an effect on
convalescence and functional results.
Hypotheses
Alternative hypothesis (H1)
The additional use of a chitosan nerve tube in the pri-
mary microsurgical repair of traumatic sensory nerve le-
sions of the hand without a gap will be superior
compared with microsurgical repair alone.
Null hypothesis (H0)
The additional use of a Chitosan nerve tube in the pri-
mary microsurgical repair of traumatic sensory nerve le-
sions of the hand without a gap will be equal to or
inferior to microsurgical repair alone.
Methods/Design
Design of the study and setting
To answer the question of whether the additional use of
a chitosan nerve tube in primary microsurgical repair of
traumatic sensory nerve lesions of the hand without a
gap will improve the recovery of sensitivity, a random-
ized controlled multicenter trial with parallel group de-
sign was planned to show superiority for the additional
use of a nerve tube. This study will enroll participants
with traumatic sensory nerve lesions from three Centers:
the BG Trauma Center Ludwigshafen (Ludwigshafen,
Germany), BG Trauma Center Frankfurt am Main
(Frankfurt am Main, Germany), and BG Bergmannsheil
Bochum (Bochum, Germany). Trauma Center Ludwigs-
hafen will be the executive study center.
Screening
After being informed about the study and its potential
risks, all individuals with traumatic sensory nerve lesions
of the hand without a gap will be consecutively screened
for eligibility until the recruitment period is over.
Informed consent comprises a description of the
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procedures and objectives of the study and the follow-up
period. Patients are informed that participation is com-
pletely voluntary and does not come with direct benefits
and that denial does not come with disadvantages for
the participant. The use by the trial of an already accre-
dited and CE-certified product will be explained but in a
blinded study setting. Potential adverse events regarding
surgery in general and regarding the implant in particu-
lar are explained. The participants have to give their
assent for blinded therapy and for the follow-ups. Partic-
ipants are instructed to report any exceptional events
immediately to the study center. Screening will be per-
formed by younger physicians in the emergency ward
who are not involved in randomization, surgery, or
follow-up. A case report form will be prepared that will
be used for the whole investigation.
Recruitment
A two-phase recruitment will be conducted with a pre-
operative and intraoperative survey. After an individual
has been found to be eligible by checking the preopera-
tive inclusion and exclusion criteria, immediate operative
treatment will follow. In the second phase of recruit-
ment, the surgeon will explore the wounds and check
the intraoperative inclusion and exclusion criteria. The
surgeons are experienced physicians and are not in-
volved in the screening or follow-up.
Randomization
Finally, the enrolled participants will be randomized in a
1:1 ratio by alternating lists in the operating room to pri-
mary microsurgical repair with the additional use of a
chitosan nerve tube or direct tension-free microsurgical
repair of the nerve alone. Final enrollment and
randomization following a fixed scheme will be per-
formed by experienced surgeons who are not involved in
the screening or follow-up. The CRFs will be accom-
plished for follow-up.
Blinding
The kind of intervention is blinded for the participant and
for the follow-up investigator, who was not involved in the
surgery. In all study centers, medical postgraduates were
employed for the follow-up examination. These raters are
explicitly excluded from the screening, randomization,
and operative procedure. The randomization list is kept
locked in the operating room and is only available to the
trial leaders and the surgeons for the process of
randomization. After enrollment, only a running number
on the CRFs will identify the participant’s position in
the list. The rater only has access to the CRFs and not
to the randomization list. Adherence to chronological
randomization by the list will be monitored by an execu-
tive study center. The operation record will only include
information about participation in the trial but will not in-
clude information about dedicated group. Unblinding is
only permitted after dropout or after completion of the
trial and can only be performed by the trial leaders.
Figure 1 shows the study flowchart.
Participants
All individuals with a fresh traumatic wound of the hand
and with the clinical suspicion of traumatic sensory
nerve lesions of the hand without a gap will be consecu-
tively screened for eligibility during the preoperative and
intraoperative periods.
Preoperative inclusion criteria are as follows:
1. Clinical suspicion of traumatic sensory nerve lesions
of the hand without a gap (lesion from the distal
area of the carpal tunnel to the end finger joint with
complete loss of a nerve-specific receptive field of
the finger).
2. Age between 18 and 67 years.
3. Trauma occurred in the previous 72 h.
4. Signed informed consent.
Preoperative exclusion criteria are as follows:
1. Amputated or avascular fingers.
2. Infection of the wound.
3. Known pre-existing impaired sensibility of the in-
jured finger or the opposite side.
4. Allergy to chitosan.
5. Pregnancy.
6. Known immunodeficiency.
7. Participation in other trials.
Intraoperative inclusion criteria are as follows:
1. Verification of a traumatic sensory nerve lesion of
the hand without a gap.
2. Nerve can be sutured in end-to-end fashion.
Intraoperative exclusion criteria are as follows:
1. Avascular fingers.
2. Multiple nerve lesions, which cannot be randomized
uniformly.
3. Nerve injuries with a gap.
Outcomes
The primary study objective is the recovery of sensitivity.
The assessment will follow the guidelines developed by
Rosén [19]. Recovery of sensibility will be assessed by
static two-point discrimination (tactile gnosis) and the
Semmes Weinstein method (sensory re-innervation).
The static two-point discrimination (2PD) after 6 months
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will be the primary outcome parameter. The 2PD does
characterize the sensory capability of the injured finger
and is a standard method used in the past for clinical as-
sessment of a variety of artificial nerve tubes [14]. The
distance between the lesion and the finger pulp will be
attributed in the statistical analysis.
Sensory re-innervation, DASH-score, grip strength,
total active range of motion, pain, cold intolerance and
hypersensitivity, and the appearance of neuroma will be
secondary outcome parameters.
All outcome parameters are frequently used in hand
surgery research.
Interventions
Surgery will be performed in plexus anesthesia or under
general anesthesia, depending on the individual’s request
and anesthesiologist’s decision, with the use of a tourniquet
in a bloodless field. The wound first will be cleaned by
flushing and surgical debridement and then explored via
Brunner’s incisions [20] using loupes. The injured nerve
will be inspected and checked for intraoperative eligibility.
Final enrollment and randomization is carried out intraop-
eratively. Further treatment depends on the dedicated
group. If more than one nerve is injured, all the nerves of
one individual will be treated in the same fashion. The kind
of intervention is blinded for the participant.
Experimental group
Participants who are allocated to the experimental group
will be treated with an additional chitosan nerve tube. The
injured nerve will be exposed and neurolysed for a distance
of 2 cm on each side of the lesion. From this point forward,
a microscope will be used. The injured ends of the nerve
will be sparingly freshened. The chitosan implant will be
pre-soaked for 10 minutes in saline. Afterward, the implant
(with a length of 1 cm and an inner diameter of 2.1 mm)
will be imposed on the proximal nerve stump. A complete
tension-free epineural coaptation of the nerve ends will fol-
low, using several 9–0 USP (United States Pharmacopoeia-
System) nylon micro-sutures (German Sutures SAS, La
Barbiniere, Beaurepaire, France).
Finally, the nerve tube will be positioned at the site
of the suture and fixed to the epineurium with a single
stitch on each side using a 9–0 USP (United States
Pharmacopoeia-System) nylon micro-suture. The use of
the chitosan-based nerve tube is already an authorized
and CE-certified German medical product (Reaxon® Nerve
Guide, Medovent, Mainz, Rheinland-Pfalz, Germany)
All patients with a fresh traumatic wound of the hand and with the clinical suspicion of a sensory nerve lesion
Assessment preoperative eligibility criteria
Operative exploration of the wound
Assessment intraoperative eligibility criteria
Intraoperative randomization by alternating lists
Experimental Arm
(50 patients)
Microsurgical repair with the 





Fig. 1 Study flowchart
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Active comparator group
Participants who were allocated to an active comparator
group will be treated by standard treatment without
using an additional chitosan nerve tube. The injured
nerve will be exposed and neurolysed for a distance of
approximately 2 cm on each side of the lesion. A micro-
scope will be used from this point onward. The injured
ends of the nerve will be sparingly freshened. A tension-
free epineural coaptation of the nerve ends using several
9–0 USP (United States Pharmacopoeia-System) nylon
micro-sutures will complete the nerve repair (German
Sutures SAS, La Barbiniere, Beaurepaire, France).
Other concomitant injuries will be treated independ-
ently of the study protocol in the same session.
Follow-up
During follow-up, the prepared CRFs will be used by the
rater. These CRFs will already include age, gender, pro-
fession and current activity, mechanism of the accident,
handedness, medical history concerning the hands, date
and time of injury, injured side, injured finger, injured
nerve, concomitant trauma, and distance from lesion to
finger pulp.
Follow-up examinations will be performed after 3, 6, 12,
and 24 months. The parameters described below will be
measured at 3, 6, 12 and 24 months. Each assessment will
take approximately 45 min. In all study centers, medical
postgraduates have been employed for the follow-up
examination. These raters are explicitly excluded from the
screening, randomization, and operative procedure.
Tactile gnosis: static two-point discrimination (2PD)
The ability of perception of either one or two points of
touch will be assessed using a compass (NCDMedical/Pres-
tige, Los Angeles, CA, USA). Participants will sit in front of
the rater with the dorsum of the hand on the table. Test will
be performed on the halves of finger pulps with preopera-
tively failed nerve-specific receptive fields and on the correl-
ating finger pulps of the contralateral hand. Pressure is
defined by self-weight of the compass (10 g). Two points
will be applied in a longitudinal direction with decreasing
distance between them until they are perceived as one
point. Final distance (in mm) will be the final value. The
2PD measured at 6 months will be the primary outcome
parameter; the other values measured at 3, 12 or 24 months
will be regarded as secondary outcome parameters.
Sensory re-innervation: Semmes Weinstein method
A monofilament is pressed against the halves of the finger
pulps with preoperatively failed nerve-specific receptive
fields and on the correlating finger pulps of the con-
tralateral hand starting with the thinnest filament.
Depending on the response, thicker ligaments are applied
until the participant feels the pressure. Six kit
monofilaments (Patterson Medical, Warrenville, IL, USA)
will be used. Value is measured in grades as follows:
0 not testable
1 filament 6.65 = perception of deep pressure
2 filament 4.56 = no protective sensation
3 filament 4.31 = diminished protective sensation
4 filament 3.61 = diminished perception of light touch
5 filament 2.83 = normal perception of light touch
The sensory re-innervation measured by the Semmes
Weinstein method is a secondary outcome parameter.
Disabilities of the arm, shoulder, and hand (DASH)
Individuals will self-report their disabilities in activities
of daily living by using a DASH (disabilities of the arm,
shoulder, and hand) questionnaire [21] in its validated
German version [22]. The questionnaire consists of 30
items regarding the requirements of daily life. Optional
sport and music modules also exist that are not part of
the scoring system. Individuals will assess each item
using a scoring system with a range between 1 (no prob-
lem with the activity) and 5 (activity is not possible any
more). Which hand is used for the activity is not rele-
vant. The assigned values for all completed responses
are simply summed and averaged, producing a score out
of five. This value is then transformed to a score out of
100 by subtracting one and multiplying by 25, resulting in
a DASH score range of 0 to 100. A higher score indicates
greater disability. The disabilities of the arm, shoulder, and
hand questionnaire (DASH) is a suitable indicator for the
burden of the disease by handicaps of the hand [21]. The
DASH-score will be a secondary endpoint.
Grip strength
Grip strength will be measured with a Jamar dynamom-
eter (Sammons Preston Inc., Bolinbrook, IL, USA) in
stage II. Participants will sit in front of the rater with el-
bows close fitting to the body and wrists in neutral pos-
ition. Participants will be requested to press the
dynamometer as hard as they can. Three trials with each
hand will be carried out. The highest trial will be valued
and will be compared with the uninjured hand. Grip
strength measured as percentage compared to the
contralateral hand will be a secondary endpoint.
Total active range of motion
Total active range of motion of the injured fingers and
of the corresponding contralateral fingers will be mea-
sured with a goniometer for small joints (Fabrication En-
terprises, White Plains, NY, USA). Participants will sit in
front of the rater, elbow on a table, palm of the hand
upturned. The arms of the goniometer will be laid along
extension side. The total active range of motion is calcu-
lated by summation of the range of motions for flexion
and extension of all joints of the concerned finger. The
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total active range of motion will be a secondary
endpoint.
Pain, cold intolerance, and hypersensitivity
Individuals will be asked to self-report pain, cold intoler-
ance and hypersensitivity experienced in the last week
on a 100-mm visual analog scale, ranging from 0 (no
symptoms) up to 10 (maximum of symptoms) by draw-
ing a point. Visual analog scales are well validated for
the measurement of acute and chronic pain [23]. Pain,
cold intolerance, and hypersensitivity will be secondary
endpoints.
Appearance of neuroma
The existence of a neuroma will be assessed by local per-
cussion of the injured nerve site. Electrifying pain will be
valued as suspicious for a neuroma. These findings will
be verified by neurosonography (linear device, 14 MHz
frequency). A final data report will include the count of
clinical suspicious neuroma and the count of verified
neuroma by sonography. The appearance of neuroma
will be a secondary endpoint.
Table 1 summarizes study outcome measures.
In addition, adverse events (any type of revision sur-
gery, incidence of postoperative hematoma, deep wound
infections, disturbances of scar formation such as hyper-
trophic or instable scars) will be recorded during the
hospital stay (approximately 5 days) and retrospectively
in the follow-ups. Revision surgery of one affected site
will be considered as an adverse event even in cases of
multiple nerve injuries. Furthermore, the number of pre-
and post-randomization dropouts will be registered and
analyzed in a descriptive statistic.
Sample size/power calculation
Assumptions for the primary outcome parameter of the
standard treatment can be made from the literature [2, 14]
and from our own patients. The mean of 2-PD after
6 months is approximately 8 mm with a standard deviation
of 3 mm. A decrease of 2 mm in the 2-PD would be clinic-
ally relevant [16] and is assumed for the experimental inter-
vention. Using a two-sided t-test with a level of 0.05 and a
power of 80 %, 37 individuals per group will be required in
order to show superiority. In order to compensate for loss
to follow-up, 50 individuals per group will be randomized.
Before implementing the trial design, we analyzed the
computerized medical records of our patients retrospect-
ively, to determine how many individuals would have fit
our scheme of inclusion and non-inclusion criteria per year.
We discovered that we could have included at least 50 indi-
viduals per year in the last 3 years. With respect to the
unequal number of hand surgical cases in the three centers,
the intention is to enroll 100 individuals per year: 50 indi-
viduals in the BG Trauma Center Ludwigshafen, 25 individ-
uals in the BG Trauma Center Frankfurt am Main, and 25
individuals in the BG Trauma Center Bochum. The study
is intended to take place over a period of 36 months:
12 months for recruitment of all individuals, 18 months
from the beginning of the trial for completion of the pri-
mary outcome parameter, and 36 months from the begin-
ning of the trial to the completion of all follow-ups.
Statistical analysis
The primary endpoint will be tested in the per-protocol
set via an analysis of covariance with center as factor and
distance between lesion and finger pulp as covariate. The
test in the full analysis set is to be considered as the sensi-
tivity analysis. Secondary endpoints will be described
Table 1 Study outcome measures
Item Outcome measurement [unit] Time point of measurement Primary/secondary outcome
parameter?
Tactile gnosis** Static 2-point-discrimination [mm] at 6 months postoperatively** primary**
Tactile gnosis** Static 2-point-discrimination [mm] at 3, 12, and 24 months
postoperatively**
secondary**
Sensory re-innervation Semmes Weinstein method [grading] at 3, 6, 12, and 24 months
postoperatively
secondary
Disabilities in activities of daily
living
DASH questionnaire [score] at 3, 6, 12, and 24 months
postoperatively
secondary
Grip strength Jamar dynamometer [kg; percentage of
contralateral side]
at 3, 6, 12, and 24 months
postoperatively
secondary





Visual analog scales [points out of ten] at 3, 6, 12, and 24 months
postoperatively
secondary
Appearance of neuroma Clinical examination and sonography [count] at 3, 6, 12, and 24 months
postoperatively
secondary
** Tactile gnosis measured by static two-point-discrimination 6 months postoperatively will be considered as the primary outcome parameter. Tactile gnosis**
measured by the static two-point discrimination at 3, 12, and 24 months postoperatively will be considered as the secondary outcome parameters
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statistically without confirmatory analysis. Adverse events
will be listed with detailed information concerning sort,
timing, severity, and mandatory countermeasures.
Data collection and monitoring
Data will be collected in standardized CRFs according to
European standards (DIN EN ISO 14155) and Good
Clinical Practice recommendations. CRFs will be trans-
mitted electronically to the executive study center in
Ludwigshafen and will be checked there for integrity,
quality, and consistency. The executive study center will
also ensure standardization of the registry process, op-
erative procedure, and follow-up in all participating cen-
ters by periodic monitoring. Furthermore, written
instructions and a course of instruction will be provided
to each investigator. Data will be collected and analyzed
in the executive study center. CRFs will also used for
reporting dropouts and for reporting adverse events.
Ethical considerations
This study is being conducted in accordance with the prin-
ciples of the Declaration of Helsinki and Good Clinical
Practice guidelines. The study was approved by a German
Ethics Committee (Ethics Committee of Rhineland-
Palatinate, Mainz, Germany). Prior to randomization, writ-
ten informed consent will be obtained from all participants.
No expenses will be paid at all.
Discussion
Standard therapy for traumatic sensory nerve lesions of
the hand includes a direct tension-free microsurgical re-
pair for lesions without a gap and autologous nerve
grafting from another body region for lesions with a gap
[6]. Alternatively, nerve gaps are increasingly recon-
structed using nerve tubes to prevent donor site morbid-
ity. A recent meta-analysis shows good and excellent
clinical results for this approach [14]. However, pro-
spective controlled single trials are still lacking, and
hardly any systematic comparison of standard treatment
and the use of nerve tubes are available [14]. The pro-
posed study will compare standard treatment and the
use of nerve tubes in a prospective controlled trial set-
ting. Some hand surgery departments also use nerve
tubes in addition to a direct nerve suture for lesions
without a gap in hopes of improving the results, but
such an effect has not yet been proven. Therefore, the
major study objective of this trial will be to answer the
question of whether the additional use of a chitosan
nerve tube in primary microsurgical repair of traumatic
sensory nerve lesions of the hand without a gap will im-
prove the recovery of sensitivity. The results will have a
direct implication on this common, but as of yet scientif-
ically unproven, practice. A potential study limitation is
an example of risk of selection bias because of the quasi-
randomization method of using alternating lists. This
limitation is due to the emergency surgery setting of the
study. Of course, the determined power of 80 % power
does also come along with a risk for type II errors of
20 %, but that is conventional for most medical trials. In
addition, there is experimental evidence that the use of a
chitosan nerve tube may improve functional outcome
and reduce the incidence of a painful neuroma [7–11,
24, 25]. The proposed study will test the chitosan-based
implant in a clinical setting. If we obtain promising re-
sults, we will expand the use of the chitosan nerve tube
to use in further studies for traumatic sensory nerve le-
sions of the hand with a gap as an alternative to autolo-
gous nerve grafting and for traumatic nerve lesions of
the forearm that include motor axons and therefore have
an even more significant burden of disease.
CONSORT statement
The authors hereby declare that final report will follow
CONSORT as well as its extension to nonpharmacologi-
cal interventions.
Trial status
The study is currently enrolling participants.
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